Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX-801 in Adult Patients with Wilson's Disease
2023-509998-23-00Phase 2Completed
- Sponsor
- Vivet Therapeutics
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of VTX-801 in Wilson disease (WD), sponsored by Vivet Therapeutics. Primary endpoint: Safety and tolerability profile. Started Apr 2024; status: completed.
02
Drugs
VTX-801
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2023-509998-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509998-23-00.